Cover ImageSALE
市場調查報告書

代謝性疾病治療藥的全球市場:2016∼2020年

Global Metabolic Disorders Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 373436
出版日期 內容資訊 英文 163 Pages
訂單完成後即時交付
價格
Back to Top
代謝性疾病治療藥的全球市場:2016∼2020年 Global Metabolic Disorders Therapeutics Market 2016-2020
出版日期: 2016年09月27日 內容資訊: 英文 163 Pages
簡介

代謝性疾病是由於化學流程的破壞和轉換在體內的細胞和體液產生的結果。原因是主要酵素的缺乏。全球代謝性疾病治療藥市場,預計2016∼2020年以4.62%的年複合成長率擴大。

本報告提供全球代謝性疾病治療藥市場相關調查,市場現狀及成長預測,市場規模,各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 產品研發線

  • 糖尿病治療藥
  • 高磷酸鹽血症
  • 抗肥胖藥

第6章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 全球代謝性疾病治療藥市場:各疾病市場區隔

  • 糖尿病
  • 肥胖
  • 高膽固醇症
  • 溶小體儲積症

第8章 全球糖尿病治療藥市場

  • 市場概要
  • 第一型糖尿病
  • 第二型糖尿病
  • 市場進入供應商

第9章 全球高膽固醇症治療藥市場

  • 市場概要
  • 市場進入供應商

第10章 全球溶小體儲積症治療藥市場

  • 市場概要
  • 市場進入供應商

第11章 全球抗肥胖藥市場

  • 市場概要
  • 市場進入供應商

第12章 全球代謝性疾病治療藥市場:各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第13章 全球代謝性疾病治療藥市場:促進要素

  • 患者支援計劃
  • 對罕見疾病的特殊的法律規章指定
  • 藥物開發的產學聯合增加

第14章 促進要素的影響

第15章 全球代謝性疾病治療藥市場:課題

  • 適合性和遵守率低
  • 治療費高
  • 胰島素的複雜保存條件與經銷政策

第16章 促進要素與課題的影響

第17章 全球代謝性疾病治療藥市場:趨勢

第18章 供應商環境

  • 競爭模式
  • 其他值得注意的供應商

第19章 主要供應商分析

  • Novo Nordisk
  • Sanof
  • Merck
  • AstraZeneca
  • Eli Lilly

第20章 附錄

第21章 關於Technavio

目錄
Product Code: IRTNTR10218

About Metabolic Disorders

Metabolic disorders occur as a result of disruption of chemical processes and conversions occurring in the cells and fluids of the body. This is mainly because of defects in the enzyme; all process in the body are controlled by enzymes. Any disruption in the pathways involved in the development and metabolism of carbohydrates, proteins, fats, and nucleic acids, results in the development of metabolic disorders.

Technavio's analysts forecast the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global metabolic disorders therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of various metabolic disorders including diabetes, obesity, lysosomal storage diseases, and hypercholesterolemia.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Metabolic Disorders Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Novo Nordisk
  • Sanofi
  • Merck
  • AstraZeneca
  • Eli Lilly

Other Prominent Vendors

  • AbbVie
  • Actelion Pharmaceuticals
  • Adocia
  • Aegerion Pharmaceuticals
  • Akros Pharma
  • Alnylam Pharmaceuticals
  • Amarin
  • nAmgen
  • Amicus Therapeutics
  • Arbutus Biopharma
  • Arena Pharmaceuticals
  • Astellas Pharma
  • Atheronova
  • Aurobindo Pharma
  • Baxalta
  • Belrose Pharma
  • BHV Pharma
  • Biocon
  • Biodel
  • BioMarin
  • Bionaturis
  • Biosidus
  • Biospherics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis Therapeutics
  • Chipscreen Biosciences
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Concord Biotech
  • ConjuChem
  • CureDm
  • CymaBay Therapeutics
  • Daewoong
  • Daiichi Sankyo
  • Dance Biopharm
  • DiaMedica
  • Diamyd Therapeutics
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dong-A ST
  • Eisai
  • Elcelyx Therapeutics
  • Esperion Therapeutics
  • Exsulin
  • F. Hoffmann-La Roche
  • Gan & Lee Pharmaceuticals
  • Generex Biotechnology
  • Genfit
  • GlaxoSmithKline
  • HanAll BioPharma
  • Hanmi Pharmaceutical Company
  • Hua Medicine
  • Iltoo Pharma
  • Intarcia Therapeutics
  • InteKrin Therapeutics
  • Intrexon
  • Ionis Pharmaceuticals
  • Islet Sciences
  • ISU Abxis
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • JCR Pharmaceuticals
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kamada
  • KinDex Pharmaceuticals
  • Kissei
  • Kotobuki
  • Kowa Company
  • Laboratoires SMB
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • Living Cell Technologies
  • Livzon
  • LIXTE Biotechnology
  • Lupin
  • MacroGenics
  • Madrigal Pharmaceuticals
  • MannKind
  • MedImmune
  • Melior Pharmaceuticals
  • Merrion Pharmaceuticals
  • Merz Pharmaceuticals
  • Metabolic Solutions Development Company
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Neothetics
  • Neuraltus Pharmaceuticals
  • NGM Biopharmaceuticals
  • NGM Biopharmaceuticals
  • Norgine BV
  • Novartis
  • NuSirt Biopharma
  • Oramed
  • Orexigen Therapeutics
  • Osiris Therapeutics
  • Peptron
  • Perle Biosciences
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Poxel
  • Protalix Biotherapeutics
  • Raptor
  • Recordati
  • Regeneron Pharmaceuticals
  • Regeneron Pharmaceuticals
  • REGiMMUNE
  • Rhythm Pharmaceuticals
  • Saniona
  • Santaris Pharma
  • Santaris Pharma
  • Serometrix
  • Shionogi
  • Shire
  • Sigma-Tau
  • Sirona Biochem
  • Strongbridge Biopharma
  • SUN Pharma
  • Takeda
  • Teva
  • Thera technologies
  • Theracos
  • Toleranzia
  • Tolerion
  • Torrent Pharmaceuticals
  • Transition Therapeutics
  • UCB
  • Utrecht Holdings
  • VeroScience
  • Vivus
  • vTv Therapeutics
  • XBiotech
  • Xeris Pharmaceuticals
  • XOMA
  • Zafgen
  • Zydus Cadila

Market driver

  • Increase in academia-industry collaborations for drug development
  • For a full, detailed list, view our report

Market challenge

  • Low compliance and adherence rates
  • For a full, detailed list, view our report

Market trend

  • Increase in academia-industry collaborations for drug development
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Pipeline portfolio

  • Pipeline portfolio: Global diabetes drugs market
  • Pipeline portfolio: Global hyperphosphatemia drugs market
  • Pipeline portfolio: Global anti-obesity drugs market

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Market segmentation by type of disease

  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal storage diseases

PART 08: Global diabetes drugs market

  • Market overview
  • Global type 1 diabetes market
  • Global type 2 diabetes drugs market
  • Vendors in global diabetes drugs market

PART 09: Global hypercholesterolemia drugs market

  • Market overview
  • Vendors in global hypercholesterolemia drugs market

PART 10: Global lysosomal storage diseases market

  • Market overview
  • Vendors in global lysosomal storage disorders drugs market

PART 11: Global anti-obesity drugs market

  • Market overview
  • Vendors in global anti-obesity drugs market

PART 12: Geographical segmentation

  • Global metabolic disorders therapeutics market by geography 2015-2020
  • Metabolic disorders therapeutics market in Americas
  • Metabolic disorders therapeutics market in EMEA
  • Metabolic disorders therapeutics market in APAC

PART 13: Market drivers

  • Patient assistance programs
  • Special regulatory designations for rare diseases
  • Increase in academia-industry collaborations for drug development

PART 14: Impact of drivers

PART 15: Market challenges

  • Low compliance and adherence rates
  • High cost of therapies
  • Complex storage conditions and distribution policies for insulin

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Focus on oral insulin therapies
  • Strong and diversified pipeline portfolio
  • Strategic collaborations and acquisitions

PART 18: Vendor landscape

  • Competitive scenario
  • Other prominent vendors
  • PART 19: Key vendor analysis
  • Novo Nordisk
  • Sanof
  • Merck
  • AstraZeneca
  • Eli Lilly

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria and customer segments for metabolic disorder drugsKey buying criteria for metabolic disorders drugs 2015
  • Exhibit 03: Impact of key customer segments on market 2015
  • Exhibit 04: Global metabolic disorders therapeutic market snapshot: Developed and emerging markets 2015
  • Exhibit 05: Global metabolic disorders therapeutics market 2015-2020 ($ billions)
  • Exhibit 06: Opportunity analysis: Global metabolic disorders therapeutics market
  • Exhibit 07: Global metabolic disorders therapeutics market: Growth cycle analysis
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Global metabolic disorders therapeutics market by type of disease
  • Exhibit 10: Global metabolic disorders therapeutics market by type (2015-2020)
  • Exhibit 11: Global metabolic disorders therapeutics market n growth lifecycle analysis
  • Exhibit 12: Top selling diabetes drugs based on sales 2015 ($ billions)
  • Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
  • Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 15: Global type 1 diabetes market 2015-2020 ($ billions)
  • Exhibit 16: Global type 2 diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 17: Market share analysis of vendors in global diabetes drugs market
  • Exhibit 18: Revenues from the sales of top five products in global diabetes drugs market 2013-2015 ($ billions)
  • Exhibit 19: Revenues from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
  • Exhibit 20: Market dynamics of hypercholesterolemia drugs
  • Exhibit 21: Percentage share of hypercholesterolemia drugs by drug class 2015
  • Exhibit 22: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
  • Exhibit 23: Market share analysis of global hypercholesterolemia drugs market 2015
  • Exhibit 24: Products offered by major vendors in global hypercholesterolemia drugs market
  • Exhibit 25: Global lysosomal storage diseases drugs market 2015-2020 ($ billions)
  • Exhibit 26: Key events in treatment of lysosomal storage diseases
  • Exhibit 27: Products offered by major vendors in global lysosomal storage disorders drugs market
  • Exhibit 28: Global anti-obesity drugs market 2015-2020 ($ millions)
  • Exhibit 29: Products offered by major vendors in global anti-obesity drugs market
  • Exhibit 30: Global metabolic disorders therapeutics market by geography 2015-2020
  • Exhibit 31: Global metabolic disorder therapeutics market by geography 2015 and 2020
  • Exhibit 32: Global metabolic disorder therapeutics market by geography 2015-2020 ($ billions)
  • Exhibit 33: Global share of metabolic disorder therapeutics market by geography 2015
  • Exhibit 34: Global share of various metabolic disorder therapeutics market by geography based on disease type 2015
  • Exhibit 35: Global metabolic disorders therapeutics market by region: Market growth lifecycle analysis 2015
  • Exhibit 36: Metabolic disorder therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Prevalence of obesity in various countries in Europe 2025
  • Exhibit 38: Metabolic disorders therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Metabolic disorder therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 40: Prevalence of diabetes in selected countries in APAC 2007 and 2025
  • Exhibit 41: Few metabolic disorder drugs with patient assistance programs
  • Exhibit 42: Impact of drivers
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Oral insulin pipeline portfolio
  • Exhibit 45: Some investigational molecules for metabolic disorders and their mechanisms
  • Exhibit 46: Key vendors ranking 2015
  • Exhibit 47: Geographical presence of key vendors
  • Exhibit 48: Competitive scenario of global metabolic disorders therapeutics market vendors 2015-2020
  • Exhibit 49: Novo Nordisk: Profile
  • Exhibit 50: Novo Nordisk: Strength analysis
  • Exhibit 51: Novo Nordisk: Growth strategy matrix
  • Exhibit 52: Novo Nordisk: Growth opportunity assessment
  • Exhibit 53: Novo Nordisk: Business segmentation by revenue 2015
  • Exhibit 54: Novo Nordisk: Key products in diabetes and obesity care
  • Exhibit 55: Novo Nordisk: YoY growth and revenue generated from net product sales of human insulins 2012-2015 ($ billions)
  • Exhibit 56: Novo Nordisk: YoY growth and revenue generated from net product sales of Levemir 2012-2015 ($ billions)
  • Exhibit 57: Novo Nordisk: YoY growth and revenue of NovoRapid/ NovoLog 2012-2015 ($ billions)
  • Exhibit 58: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog Mix 2012-2015 ($ billions)
  • Exhibit 59: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
  • Exhibit 60: Novo Nordisk: YoY growth and revenue of Victoza 2012-2015 ($ billions)
  • Exhibit 61: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and Prandimet 2012-2014 ($ billions)
  • Exhibit 62: Sanofi: Business segmentation by revenue 2015
  • Exhibit 63: Sanofi: Profile
  • Exhibit 64: Sanofi: Strength analysis
  • Exhibit 65: Sanofi growth strategy matrix
  • Exhibit 66: Sanofi: Growth opportunity assessment
  • Exhibit 67: Key product offerings in diabetes market ($ billions)
  • Exhibit 68: Sanofi: YoY revenue and growth rate of Lantus 2012-2015 ($ billions)
  • Exhibit 69: Sanofi: YoY revenue and growth rate of Amaryl 2012-2015 ($ billions)
  • Exhibit 70: Sanofi: YoY revenue and growth rate of Apidra 2012-2015 ($ billions)
  • Exhibit 71: Sanofi: YoY revenue and growth rate of Insuman 2012-2015 ($ billions)
  • Exhibit 72: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
  • Exhibit 73: Sanofi: Revenues of lysosomal storage diseases drugs of Genzyme, 2015
  • Exhibit 74: Merck: Strength profile
  • Exhibit 75: Merck: Strength analysis
  • Exhibit 76: Merck: Growth strategy matrix
  • Exhibit 77: Merck: Opportunity assessment
  • Exhibit 78: Top selling diabetes drugs in 2015
  • Exhibit 79: Merck: Diabetes segmentation by revenue 2015
  • Exhibit 80: Merck: YoY growth and revenue of Janumet 2012-2015 ($ billions)
  • Exhibit 81: Merck: YoY growth and revenue of Januvia 2012-2015 ($ billions)
  • Exhibit 82: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
  • Exhibit 83: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
  • Exhibit 84: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
  • Exhibit 85: AstraZeneca: Profile
  • Exhibit 86: AstraZeneca: Strength analysis
  • Exhibit 87: AstraZeneca: Growth strategy matrix
  • Exhibit 88: AstraZeneca: Opportunity assessment
  • Exhibit 89: Top selling diabetes drugs in 2015 ($ billions)
  • Exhibit 90: AstraZeneca: Byetta YoY growth and revenues 2012-2015 ($ billions)
  • Exhibit 91: Astrazeneca: Byetta YoY growth rate and revenues in the US ($ billions)
  • Exhibit 92: AstraZeneca: Bydureon YoY revenues and growth rate 2012-2015 ($ billions)
  • Exhibit 93: AstraZeneca: Onglyza YoY revenue and growth rate 2012-2015 ($ billions)
  • Exhibit 94: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
  • Exhibit 95: AstraZeneca: Geographical segmentation of Crestor 2015 by revenue
  • Exhibit 96: Eli Lilly: Profile
  • Exhibit 97: Eli Lilly: Strength analysis
  • Exhibit 98: Eli Lilly growth strategy matrix
  • Exhibit 99: Eli Lilly: Opportunity assessment
  • Exhibit 100: Top selling diabetic drugs 2015 ($ billions)
  • Exhibit 101: Eli Lilly: YoY revenue and growth rate of Humalog 2012-2015 ($ billions)
  • Exhibit 102: Eli Lilly: YoY revenue and growth rate of Humulin 2012-2015 ($ billions)
  • Exhibit 103: Eli Lilly: YoY revenue and growth rate of Tradjenta 2012-2015 ($ billions)
  • Exhibit 104: Eli Lilly: YoY revenue of Trylicity 2014-2015 ($ millions)
Back to Top